Health Outcomes Research in Medicine
Volume 2, Issue 4 , Pages e215-e226 , November 2011

Costs of Sequelae Associated with Invasive Meningococcal Disease: Findings from a US Managed Care Population

  • Sudeep Karve, PhD

      Affiliations

    • Health Economics – United States, RTI Health Solutions, Research Triangle Park, NC
    • Corresponding Author InformationCorresponding Author: Sudeep Karve, PhD, RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709.
    • ,
  • Derek Misurski, PhD

      Affiliations

    • Global Health Outcomes; GlaxoSmithKline, Philadelphia, PA
    • ,
  • Jacqueline Miller, MD

      Affiliations

    • Global Vaccine Development; GlaxoSmithKline, King of Prussia, PA
    • ,
  • Keith L. Davis, MA

      Affiliations

    • Health Economics – United States, RTI Health Solutions, Research Triangle Park, NC

References 

  1. Bilukha OO, Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1–21
  2. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50(Suppl 2):S37–S44
  3. O’Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: hospital case characteristics and costs by age. Value Health. 2006;9(4):236–243
  4. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–B63
  5. Centers for Disease Control and Prevention . Active Bacterial Core Surveillance Report, Emerging Infections Program Network. Neisseria meningitidis. 2008;[updated September 1, 2009]. Available at: http://www.cdc.gov/abcs/reports-findings/survreports/mening08.htmlLast accessed April 4, 2011
  6. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184–191
  7. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44(5):657–663
  8. Mutonga DM, Pimentel G, Muindi J, et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am J Trop Med Hyg. 2009;80(4):619–624
  9. Centers for Disease Control and Prevention . Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children—United States, 1998-2000. MMWR Morb Mortal Wkly Rep. 2002;51(11):234–237
  10. Lexau CA, Lynfield R, Danila R, et al. Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043–2051
  11. Whitney CG, Farley MM, Hadler J, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737–1746
  12. Centers for Disease Control and Prevention . Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59(9):273
  13. American Academy of Pediatrics. 2010 immunization schedules [updated February 1, 2011]. Available at: http://www.aap.org/immunization/IZSchedule.html. Last accessed April 4, 2011.
  14. Caro JJ, Möller J, Getsios D, et al. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health. 2007;7:130
  15. Centers for Disease Control and Prevention . Vaccination coverage among adolescents aged 13-17 years—United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(40):1100–1103
  16. Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med. 2006;355(14):1466–1473
  17. Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123(3):e502–e509
  18. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis. 1998;26(5):1159–1164
  19. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737–739
  20. Centers for Disease Control and Prevention . Active Bacterial Core Surveillance, Reports and Findings. Neisseria meningitidis. 1997-2008;[updated September 1, 2009]. Available at: http://www.cdc.gov/abcs/reports-findings/survreports/mening08.htmlLast accessed April 4, 2011
  21. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(5):317–328
  22. Edmond K, Dieye Y, Griffiths UK, et al. Prospective cohort study of disabling sequelae and quality of life in children with bacterial meningitis in urban Senegal. Pediatr Infect Dis J. 2010;29(11):1023–1029
  23. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Adv Ther. 2009;26(10):936–946
  24. Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health. 2010;13(4):479–486
  25. Wu EQ, Patel PA, Yu AP, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008;14(2):164–175
  26. Heyderman RS, Ben-Shlomo Y, Brennan CA, Somerset M. The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics. Arch Dis Child. 2004;89(11):1064–1068
  27. Barquet N, Domingo P, Caylà JA, et al. Meningococcal disease in a large urban population (Barcelona, 1987-1992): predictors of dismal prognosis. Barcelona Meningococcal Disease Surveillance Group. Arch Intern Med. 1999;159(19):2329–2340
  28. Buysse CM, Raat H, Hazelzet JA, et al. Long-term health status in childhood survivors of meningococcal septic shock. Arch Pediatr Adolesc Med. 2008;162(11):1036–1041
  29. Buysse CM, Oranje AP, Zuidema E, et al. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child. 2009;94(5):381–386
  30. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619
  31. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139
  32. Basu A, Manning WG. Issues for the next generation of health care cost analyses. Med Care. 2009;47(7 Suppl 1):S109–S114
  33. Fu AZ, Qiu Y, Radican L, Wells BJ. Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diabetes Care. 2009;32(12):2187–2192
  34. Wedderburn RWM. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika. 1974;61:439–447
  35. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283–295
  36. Manning WG, Mullahy J. Estimating log models: to transform or not to transform?. J Health Econ. 2001;20:461–494
  37. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr. 1981;99(4):540–545
  38. Naess A, Halstensen A, Nyland H, et al. Sequelae one year after meningococcal disease. Acta Neurol Scand. 1994;89(2):139–142
  39. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Med. 2009;7:47
  40. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378–1388
  41. Tsolia MN, Theodoridou M, Tzanakaki G, et al. Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis. 2006;25(7):449–456
  42. de Souza AL, de Oliveira AC, Romano CC, Sztajnbok J, Duarte AJ, Seguro AC. Interleukin-6 activation in ischemic stroke caused by Neisseria meningitidis serogroup C. Int J Cardiol. 2008;127(3):e160–e163
  43. Gironell A, Domingo P, Mancebo J, Coll P, Martí-Vilalta JL. Hemorrhagic stroke as a complication of bacterial meningitis in adults: report of three cases and review. Clin Infect Dis. 1995;21(6):1488–1491
  44. Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46(1):1–13

 Funding for this study was provided by GlaxoSmithKline. GlaxoSmithKline also is conducting clinical research in meningococcal disease. The publication of the study results is not contingent upon the sponsors’ approval or censorship of the manuscript. Sudeep Karve, Keith Davis, and Derek Misurski were the primary developers of the study design. As principal investigator, Sudeep Karve had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Keith Davis and Sudeep Karve led all statistical analyses. Sudeep Karve also served as the primary writer in drafting the manuscript text and in interpreting the findings. Derek Misurski also assisted in obtaining the study data. Derek Misurski and Jacqueline Miller assisted in interpreting the study findings and drafting the manuscript text; they also served as the primary reviewers of the manuscript text. All authors were responsible for approving the manuscript and its contents.

 Sudeep Karve and Keith Davis are employees of RTI Health Solutions, an independent contract research organization that has received research funding from GlaxoSmithKline for this study. Derek Misurski and Jacqueline Miller are GlaxoSmithKline employees and shareholders.

PII: S1877-1319(11)00026-7

doi: 10.1016/j.ehrm.2011.08.001

Health Outcomes Research in Medicine
Volume 2, Issue 4 , Pages e215-e226 , November 2011

Article Tools

* Image Usage & Resolution